Why Is DEFINIUM THERAPEUTIC (DFTX) Stock Up Today?
By the Top Tier Newswire AI Desk · September 14, 2026 at 9:40 AM ET · reviewed against 11 wire stories
DEFINIUM THERAPEUTIC (DFTX) is up +8.36% in the latest session. Our newswire has captured 11 stories on DFTX across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Definium Therapeutics (DFTX) shares surged 8.36% to $42.14 on Friday, driven by the company’s announcement that its Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met both primary and key secondary endpoints. The stock opened with a 17.2% gap up from the prior close and traded as high as $47.50 before retreating to close near $42.11. The positive topline results from the trial have generated strong investor interest.
What Happened
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT, an oral synthetic lysergic acid diethylamide (LSD) derivative, for the treatment of generalized anxiety disorder. The trial met its primary and key secondary endpoints, reinforcing the drug’s potential as a treatment for anxiety. The results were disclosed in a Form 8-K filed with the SEC on September 14, 2026, and were also highlighted in multiple reports across the financial wire. The Fly and Reuters both confirmed the success of the trial, with Reuters noting that the drug lowered anxiety symptoms in a second successful late-stage study. The news comes after the company previously received FDA Breakthrough Therapy Designation for DT120 ODT.
What The Data Shows
The stock opened at $45.56, reflecting a 17.2% gap from the prior close of $38.89. It reached an intraday high of $47.50 at 7:30 AM ET but declined throughout the session, closing at $42.11. The volume of 1.2 million shares was 0.5 times the 3-month daily average, indicating moderate institutional and retail participation. Over the past 8 sessions, the stock has risen 11.2% from $38.90 to $43.24. The 52-week range is $8.77 to $49.70, and the stock printed one fresh 52-week high and three fresh 52-week lows on September 14. Insider transactions over the last 90 days include six sales totaling $3.3 million, with no insider purchases reported.
What To Watch
Investors should monitor the company’s next steps in the regulatory process for DT120 ODT. With no upcoming earnings date provided, the focus will remain on coverage breadth and any new developments from the FDA or clinical pipeline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Definium Therapeutics shares rise 20% after its Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met its primary and key secondary endpoints.
5h agoInvestors.comBULLISH 78Product/PR
Definium, Up 190% This Year, Succeeds Again With Synthetic LSD; Shares Fly
Definium Therapeutics' synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again.
S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead
8h agoThe FlyBULLISH 73Product/PR
Definium says Phase 3 Panorama study met primary, secondary efficacy endpoints
8h agoReutersBULLISH 67Product/PR
Definium's LSD-based drug lowers anxiety in second successful late-stage study
8h agoStockTitanBULLISH 73Product/PR
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →